Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Pfizer Inc
Recent news which mentions Pfizer Inc
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
January 08, 2024
Tags
US: News
Business
Pfizer Inc
From
CNBC.com News
Cramer names biopharma companies to watch as industry mergers start to pile up
January 05, 2024
Tags
JPMORGAN DRN
Roche Holding AG
ImmunoGen Inc
From
CNBC.com News
Cramer's week ahead: Earnings season kicks off after JPMorgan Healthcare Conference
January 05, 2024
Tags
Mad Money
Business News
Markets
From
CNBC.com News
Here are the big health sector themes to watch next year
December 22, 2023
Tags
Biotech and Pharmaceuticals
Moderna Inc
Cigna Corp
From
CNBC.com News
Single-stock ETFs tap into the market’s ‘gambling mindset,’ expert says. What investors need to know
December 20, 2023
Tags
Exchange/traded funds
Apple Inc
stocks
From
CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
December 20, 2023
Tags
Biotech and Pharmaceuticals
Health care industry
Biogen Inc
From
CNBC.com News
5 things to know before the stock market opens Monday
December 18, 2023
Tags
Politics
Technology
Novo Nordisk A/S
From
CNBC.com News
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
December 17, 2023
Tags
Pharmaceuticals
Pfizer Inc
Eli Lilly and Co
From
CNBC.com News
Pfizer shares fall as 2024 revenue and profit forecast disappoints
December 13, 2023
Tags
Abbvie Inc
Merck & Co Inc
Business News
From
CNBC.com News
Biden administration asserts power to seize drug patents in move to slash high prices
December 07, 2023
Tags
Health care industry
Biotech and Pharmaceuticals
Business News
From
CNBC.com News
Free ChatGPT may incorrectly answer drug questions, study says
December 05, 2023
Tags
Technology
Companies
Biotechnology
From
CNBC.com News
Cramer on Monday's market action: Some investors are headed for a 'nasty hangover'
December 04, 2023
Tags
Business News
Markets
Mad Money
From
CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
December 02, 2023
Tags
Abbott Laboratories
Business News
Biotech and Pharmaceuticals
From
CNBC.com News
5 things to know before the stock market opens Friday
December 01, 2023
Tags
Walt Disney Co
Business
Investment strategy
From
CNBC.com News
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
December 01, 2023
Tags
Biotech and Pharmaceuticals
Diabetes
Health care industry
From
CNBC.com News
Cramer's Lightning Round: 'I'm not a buyer' of NIO
November 30, 2023
Tags
Uranium Energy Corp
Q2 Holdings Inc
U/S/ Markets
From
CNBC.com News
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
November 30, 2023
Tags
Health care industry
Biotech and Pharmaceuticals
Seagen Inc
From
CNBC.com News
Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them
November 30, 2023
Tags
COVID/19
Business News
Biotech and Pharmaceuticals
From
CNBC.com News
Tim Cook, Elon Musk, Steve Schwarzman spotted at Xi Jinping dinner with U.S. CEOs
November 16, 2023
Tags
Politics
Visa Inc
Government and politics
From
CNBC.com News
Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
November 13, 2023
Tags
Novo Nordisk A/S
Biotechnology
Companies
From
CNBC.com News
Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
November 02, 2023
Tags
Health & Science
Pharmaceuticals
Pfizer Inc
From
CNBC.com News
Moderna posts quarterly loss as company takes $1.3 billion write-down on unused Covid shots
November 02, 2023
Tags
Health care industry
Novavax Inc
Biotech and Pharmaceuticals
From
CNBC.com News
'We are really keen to join forces with Seagen': Pfizer CEO on plans to acquire cancer drugmaker
October 31, 2023
Tickers
CEO
Tags
Pfizer Inc
Investment strategy
Business
From
CNBC.com News
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
October 31, 2023
Tags
Breaking news
Biotechnology
Companies
From
CNBC.com News
5 things to know before the stock market opens Monday
October 30, 2023
Tags
Moderna Inc
5 Things to Know
Economy
From
CNBC.com News
CNBC Daily Open: Are things about to get more difficult?
October 30, 2023
Tags
JPMORGAN DRN
Daily Open
Market Outlook
From
CNBC.com News
CNBC Daily Open: The perfect storm
October 29, 2023
Tags
Asia Markets
Prices
Pfizer Inc
From
CNBC.com News
Pfizer's combination Covid, flu vaccine will move to final-stage trial after positive data
October 26, 2023
Tags
US: News
Business
Pfizer Inc
From
CNBC.com News
Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition
October 26, 2023
Tags
Business News
Health care industry
Bristol/Myers Squibb Co
From
CNBC.com News
Merck results beat expectations on strong Keytruda, Gardasil and Covid drug growth
October 26, 2023
Tags
Moderna Inc
Biotech and Pharmaceuticals
Health care industry
From
CNBC.com News
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.